<DOC>
	<DOCNO>NCT01748487</DOCNO>
	<brief_summary>The purpose study assess efficacy safety OZURDEX ( dexamethasone intravitreal implant ) 0.7 mg administer immediately phacoemulsification intraocular lens implantation type 1 2 diabetic patient prevent occurrence post-surgical macular edema ( ME ) . Treatment group : 24 patient receive intravitreal injection OZURDEX end cataract surgery Patients see 1 week pre-operatively ( baseline visit ) , day post-surgery ( visit 1 ) , 1 week ( visit 2 ) , 1 month ( visit 3 ) 3 month ( visit 4 ) . BCVA , IOP SD-OCT perform visit .</brief_summary>
	<brief_title>The Effect Intravitreal Ozurdex DME After Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Capsule Opacification</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion Criteria 1 . Type 1 2 diabetic patient cataract surgery &gt; grade 3 cataract type use Lens Opacities Classification System III . Patients onset diabetes age 30 year minimal absent endogenous insulin production classify type 1 diabetes . The remain patient classify type 2 diabetes . 2 . Diabetics include must least level 20 ( microaneurysms ) diabetic retinopathy , define Early Treatment Diabetic Retinopathy Study ( ETDRS ) . 3 . Patients must healthy enough undergo cataract surgery decide physician . 4 . Patients must 18 year old must able provide inform consent . Exclusion criteria 1 . Patients active suspect ocular periocular infection include viral disease cornea conjunctiva , include active epithelial herpes simplex keratitis ( dendritic keratitis ) , vaccinia , varicella , mycobacterial infection , fungal disease . 2 . Patients advance glaucoma . 3 . Patients know hypersensitivity component product corticosteroid . 4 . Patients ACIOL ( Anterior Chamber Intraocular Lens ) rupture posterior lens capsule 5 . Patients aphakic eye rupture posterior lens capsule . 6 . Diabetic patient without retinopathy active uncontrolled proliferative disease exclude . We exclude normal retina diabetic since feel particular risk ME compare form disease . A grade proliferative diabetic retinopathy base criterion make ETDRS study , include presence either 1/3 optic disc neovascularization Ã≠â√∂ optic disc area neovascularization anywhere elsewhere retina . 7 . Patients clinical significant macular edema ( CSME ) measure OCT prior surgery exclude . 8 . Panretinal photocoagulation within prior 3 month anticipate need panretinal photocoagulation within next 6 month . 9 . Patients retinal disease , diabetes , affect ME exclude study . 10 . Eyes uveitis , history intraocular surgery history uncontrolled glaucoma ( baseline IOP high 21 mmHg use one type glaucoma medication ) steroid responder enrol study . 11 . Eyes cataract preclude proper optical coherence tomography ( OCT ) measurement preoperatively also exclude . 12 . Patients experience longer usual operating time , complicate surgery , rupture posterior capsule , iris corneal burn manage accordingly exclude study . 13 . Patients pregnant , breast feeding , unable attend schedule followup appointment also exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>